Literature DB >> 12673103

Biliary excretion of antimicrobial drugs.

George Karachalios1, Konstantinos Charalabopoulos.   

Abstract

The development of drugs able to prevent and cure bacterial infections is one of the 20th century's major contributions to human longevity and quality of life. Antibacterial agents are among the most commonly prescribed drugs of any kind worldwide. Used appropriately, these drugs are lifesaving. To eliminate an infection as rapidly as possible, a sufficient concentration of the drug(s) chosen must reach the site of infection. Serum/tissue concentration is a result of various parameters such as absorption, excretion, protein binding and metabolic inactivation. Biliary excretion is an important route for the elimination of some drugs and drug metabolites in humans. Thus, drugs with a high bile concentration are indicated for the treatment of gallbladder infectious diseases. We present a review of a large number of antimicrobial agents most commonly used in daily clinical practice, with regard to their biliary excretion. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12673103     DOI: 10.1159/000069712

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  14 in total

1.  High Heterogeneity of Multidrug-Resistant Enterobacteriaceae Fecal Levels in Hospitalized Patients Is Partially Driven by Intravenous β-Lactams.

Authors:  Eva M González-Barberá; Jaime Sanz; Ana Djukovic; Alejandro Artacho; Iván Peñaranda; Beatriz Herrera; María José Garzón; Miguel Salavert; José Luis López-Hontangas; Karina B Xavier; Bernhard Kuster; Laurent Debrauwer; Jean-Marc Rolain; Miguel A Sanz; Joao B Xavier; Carles Ubeda
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  P1A recombinant beta-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intravenous administration of ampicillin.

Authors:  Ann-Mari Tarkkanen; Tuula Heinonen; Rain Jõgi; Silja Mentula; Michel E van der Rest; Curtis J Donskey; Tuomas Kemppainen; Konstantin Gurbanov; Carl Erik Nord
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

3.  Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.

Authors:  Kazuro Ikawa; Akira Nakashima; Norifumi Morikawa; Kayo Ikeda; Yoshiaki Murakami; Hiroki Ohge; Hartmut Derendorf; Taijiro Sueda
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

4.  Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies.

Authors:  Tracey Roberts; John F Kokai-Kun; Olivia Coughlin; Barbara Valero Lopez; Heidi Whalen; J Andrew Bristol; Steven Hubert; James Longstreth; Kenneth Lasseter; Joseph Sliman
Journal:  Clin Drug Investig       Date:  2016-09       Impact factor: 2.859

5.  Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

Authors:  Trevor N Johnson; Amin Rostami-Hodjegan; Geoffrey T Tucker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  Methods to evaluate biliary excretion of drugs in humans: an updated review.

Authors:  Giulia Ghibellini; Elaine M Leslie; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2006 May-Jun       Impact factor: 4.939

7.  An engineered live biotherapeutic for the prevention of antibiotic-induced dysbiosis.

Authors:  Andrés Cubillos-Ruiz; Miguel A Alcantar; Nina M Donghia; Pablo Cárdenas; Julian Avila-Pacheco; James J Collins
Journal:  Nat Biomed Eng       Date:  2022-04-11       Impact factor: 29.234

8.  Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions.

Authors:  Boubakar Ba; Karen Gaudin; Amélie Désiré; Thida Phoeung; Marie-Hélène Langlois; Charan R Behl; Joel Unowsky; Indravadan H Patel; A Waseem Malick; Melba Gomes; Nicholas White; Tina Kauss
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 9.  Rethinking antimicrobial stewardship paradigms in the context of the gut microbiome.

Authors:  Farah Shahi; Kelly Redeker; James Chong
Journal:  JAC Antimicrob Resist       Date:  2019-05-21

Review 10.  Role of cephalosporins in the era of Clostridium difficile infection.

Authors:  Mark H Wilcox; James D Chalmers; Carl E Nord; Jane Freeman; Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2016-09-22       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.